Sigyn Therapeutics, Inc. (SIGY) intrinsic value & 10-year financials
Sigyn Therapeutics, Inc. (SIGY) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.03
- Market cap
- $40.0K
- Revenue (FY2024)
- —
- Revenue growth (10-yr CAGR)
- 48.8%
- ROIC (10-yr avg)
- 573.8%
- Free cash flow (FY2024)
- —
SIGY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | — | -$3.3M | -$2.51 | — | — | 222.1% |
| FY2023 | — | -$4.1M | -$3.77 | — | — | 3526.9% |
| FY2022 | — | -$2.9M | -$3.13 | -$1.8M | — | -3080.3% |
| FY2021 | — | -$3.0M | — | -$1.8M | — | 823.4% |
| FY2020 | — | -$1.3M | — | — | — | 106.7% |
| FY2019 | $143.3K | -$3.1M | — | — | -361.4% | 99.6% |
| FY2018 | $28.3K | -$2.6M | — | -$289.1K | -3544.2% | 34.6% |
| FY2017 | $38.4K | -$4.3M | — | -$400.9K | -5277.4% | 145.6% |
| FY2016 | — | — | — | — | — | — |
| FY2015 | $29.2K | -$2.7M | — | -$86.3K | -7714.3% | 3285.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Sigyn Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Sigyn Therapeutics, Inc. has earned high returns on invested capital, averaging 48.2% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Over the decade, Sigyn Therapeutics, Inc. shows that management has aggressively returned capital to shareholders by retiring 99.1% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Sigyn Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-83.37 per share.